Peripheral neurotoxicity of weekly paclitaxel chemotherapy: A schedule or a dose issue?

Clinical Breast Cancer

Volumn 7, Issue 7, 2007, Pages 550-554

  Pace, Andrea ^a   Nisticò, Cecilia ^a   Cuppone, Federica ^a   Bria, Emilio ^a   Galiè, Edvina ^a   Graziano, Giuliana ^a   Natoli, Guido ^a   Sperduti, Isabella ^a   Jandolo, Bruno ^a   Calabretta, Francesca ^a   Tomao, Silverio ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Amplitude; Chemotherapy; Neurophysiology

Indexed keywords

PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; QUALITY OF LIFE;

EID: 34248232644     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.010     Document Type: Article

References (26)

1. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study in 23 patients. It J Neurol Sci 1996; 18:73-79.
2. Chaudry V, Rowinsky EK, Sartorius P, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35:304-311.
3. Guchelaar HJ, ten Napel CH, de Vries EG, et al. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 1994; 6:40-48.
4. Mielke S, Sparreboomb A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006; 42:24-30.
5. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 2004; 22:2061-2068.
6. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 2003; 61:1297-1300.
7. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41:1135-1139.
8. Marchetti R Urien S, Antonini-Cappellini G, et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002; 44:S3-S13.
9. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10:370-381.
10. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusion over 1 versus 3 h. Anticancer Drugs 2003; 14:785-792.
11. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11:4843-4850.
12. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005; 10:665-685.
13. Pace A, Bove L, Nisticò C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996; 61:409-411.
14. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: A User's Manual. 3rd ed. Boston, MA: The Health Institute, New England Medical Centre; 1994.
15. Seidman A. "Will weekly work"? Seems to be so.... . J Clin Oncol 2005; 23:5873-5874.
16. Pasquir E, Honore S, Pourroy B, et al. Anti-angiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
17. Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23:1951-1961.
18. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J Clin Oncol 2005; 23:5983-5992.
19. Seidman AD, Berry D, Cirrincione L, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22(14 suppl):14S (Abstract #512).
20. Nisticò C, Cognetti F, Frontini L, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology 2005; 68:356-363.
21. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003; 65:224-228.
22. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66:347-352.
23. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
24. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4261-4223.
25. Wist EA, Sommer HH, Ostenstad B, et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004; 43:11-14.
26. Akerley W, Herndon JE, Egorin MJ, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003; 97:2480-2486.